Chongqing Pharscin Pharmaceutical Co., Ltd.
华森制药
002907
Shenzhen Stock Exchange
Company Profile
1. Focus on Innovation: Orderly Advancement of R&D Projects The company remains highly committed to R&D innovation and continues to maintain high-intensity investment in research. During the reporting period, the company invested RMB 73.0324 million in R&D, accounting for 9.43% of total revenue, with R&D expenses representing 7.63% of revenue. In terms of innovative drug R&D technology platforms, the company is targeting the international market, pursuing First-in-Class (FIC) and Best-in-Class (BIC) projects to build a globally competitive, forward-looking, and differentiated independent R&D platform and pipeline. The company has further enhanced its Computer-Aided Multi-Dimensional Drug Discovery (CAMDD) platform and made strategic advancements in PROTAC technology, establishing a preliminary PROTAC drug R&D platform. During the reporting period, the company’s key traditional Chinese medicine (TCM) product, Ganju Bingmei Tablets, successfully obtained regulatory approval in Singapore, marking the company’s first product registered in an overseas market. As of the disclosure date of this report, other key TCM products, including Liuwei Anshen Capsules and Duliang Soft Capsules, have also received Singaporean regulatory approval. These milestones signify the company’s eligibility to sell these products in Singapore, expanding its overseas product portfolio and laying a solid foundation for future international registrations and market expansion. In April 2024, the company’s first FIC small-molecule global innovative drug (HSN003) and partial research findings from its BIC small-molecule innovative drug (HSN002) were presented in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, marking the company’s first step in aligning its innovation capabilities with international standards. In the field of generic drugs, the company has actively developed its pipeline of generics, TCMs, and FSMPs (Foods for Special Medical Purposes), focusing on fast development speed, low manufacturing costs, and high technical barriers. During the reporting period, the company advanced multiple R&D projects, with a total of 27 drug formulation and API projects and 4 FSMP projects currently in development. Among these, 6 new projects were initiated, 4 completed Chinese registration filings (including 1 FSMP), 4 completed Singaporean registrations, and 3 obtained drug approval certificates. 2. Innovative Marketing, Building Momentum for Growth Under the leadership of the Board of Directors, the company continues to uphold its operational philosophy of "Steady Operations, Innovative Development," aiming to navigate the complex and volatile economic and market environment while laying a solid foundation for high-quality growth in the future. In terms of new product commercialization, recently launched products such as Omeprazole Sodium Bicarbonate Capsules, Olmesartan Amlodipine Tablets, Pingxiao Tablets, and Xanthium Rhinitis Capsules have gradually contributed to sales revenue. Regarding channel management, the company has been actively expanding its presence in new medical institutions while deepening penetration in existing healthcare terminals. During the reporting period, the company further increased its coverage, now serving nearly 12,000 tiered public hospitals and approximately 16,000 primary healthcare institutions across China. In addition to public hospitals and grassroots medical facilities, the company has also expanded its network in private hospitals, retail pharmacies, and e-commerce platforms, creating a more diversified terminal distribution landscape. This multi-channel strategy ensures broader market access and enhances the company's ability to meet diverse patient needs, reinforcing its competitive edge in the pharmaceutical industry. 3. Efficient Production, Continuous Cost Optimization, and Building a World-Class Quality Manufacturing System The company continues to refine its production processes and quality control measures, enhancing both operational efficiency and product quality while effectively mitigating potential risks in manufacturing. Our products consistently maintain a 100% compliance rate across all critical inspections. This unwavering commitment ensures the high-quality supply of pharmaceutical products to the market. Additionally, the company is dedicated to cost optimization and efficiency improvements, implementing lean production practices and advanced quality management systems to meet international manufacturing standards. By fostering a culture of continuous improvement, we strengthen our competitiveness while maintaining strict compliance with global regulatory requirements.
Full description
Pharscin Pharma is a comprehensive pharmaceutical enterprise integrating drug research and development, production, and sales, with business operations spanning pharmaceutical industry, pharmaceutical commerce, and pharmaceutical retail. Adhering to its corporate mission of "Revitalizing National Medicine, Producing Quality Chinese Drugs, and Safeguarding Lives," the company upholds the philosophy of "Responsibility and Vitality," committing itself to meeting clinical medication needs. Over the years, the company has focused on the R&D, production, and sales of traditional Chinese medicines and chemical drugs, operating 22 production lines including tablets, granules, capsules, soft capsules, powders, powder injections, lyophilized powder injections, small-volume injections, chemical APIs, and herbal extracts. Since its establishment, the company has obtained 84 drug approval codes, with 20 specifications included in the National Essential Medicines List and 60 specifications listed in the National Reimbursement Drug List. To seize development opportunities in the health industry, the company actively identifies clinical demands and leverages its pharmaceutical expertise to enter the specialized medical nutrition (FSMP) sector. As of the disclosure date of this report, the company’s FSMP project TY005 obtained the registration certificate for formula foods for special medical purposes in February 2025. This certificate not only marks the first of its kind for the company and Chongqing but also represents a breakthrough in the FSMP field, filling a market gap in Chongqing. For years, the company has deeply cultivated key therapeutic areas such as the digestive system, neuropsychiatry, and otolaryngology, forming a complementary development strategy integrating traditional Chinese and Western medicines and a distinctive product portfolio. Through continuous innovation, the company has enriched its product pipeline, strengthened its product echelon, and built a robust portfolio of flagship products. Leading products such as WEIDIMEI , CHANGSONG (Polyethylene Glycol 4000 Powder), GANJUBINGMEIPIAN, TONGXIENINGKELI, and DULIANGRUANJIAONANG (the "Five Core Products") have gradually become dominant players in their respective segments. Meanwhile, the company’s product pipeline continues to expand into oncology and metabolic disease fields.